Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Rationale for and Development of the Pancreatic Quantitative Sensory Testing Consortium to Study Pain in Chronic Pancreatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Modified Marshall Score Predicts Mortality in Patients With Walled-off Pancreatic Necrosis Treated in an Intensive Care Unit

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fungal Infections in Patients With Walled-off Pancreatic Necrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy: a pilot study for use in focal pancreatic masses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Louise S Rasmussen
  • Claus W Fristrup
  • Benny V Jensen
  • Per Pfeiffer
  • Britta Weber
  • Mette K Yilmaz
  • Laurids Ø Poulsen
  • Morten Ladekarl
  • Kell Østerlind
  • Jim S Larsen
  • Halla Skuladottir
  • Martin Bøgsted
  • Ursula G Falkmer
Vis graf over relationer

OBJECTIVES: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age.

METHODS: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more.

RESULTS: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35).

CONCLUSIONS: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.

OriginalsprogEngelsk
TidsskriftPancreas
Vol/bind50
Udgave nummer5
Sider (fra-til)685-695
Antal sider11
ISSN0885-3177
DOI
StatusUdgivet - 22 maj 2021

Bibliografisk note

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

ID: 68136608